Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
23.86
-0.31 (-1.28%)
At close: Jan 16, 2026, 4:00 PM EST
24.00
+0.14 (0.59%)
After-hours: Jan 16, 2026, 7:50 PM EST
Alumis Employees
As of December 31, 2024, Alumis had 170 total employees, including 168 full-time and 2 part-time employees. The number of employees increased by 61 or 55.96% compared to the previous year.
Employees
170
Change (1Y)
61
Growth (1Y)
55.96%
Revenue / Employee
$130,124
Profits / Employee
-$1,442,076
Market Cap
2.97B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170 | 61 | 55.96% |
| Dec 31, 2023 | 109 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALMS News
- 7 days ago - Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 9 days ago - Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 9 days ago - Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise - Seeking Alpha
- 10 days ago - Alumis Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 10 days ago - Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
- 10 days ago - Alumis skin disease drug meets main goal of two late-stage trials - Reuters
- 10 days ago - Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program - GlobeNewsWire
- 11 days ago - Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis - GlobeNewsWire